Table 1.
Summary of demographics of cats participating in the intravenous allogeneic cryopreserved studies
| Cat no. | Group | Description | IRIS CKD stage and creatinine (mg/dl) | Treatment |
|---|---|---|---|---|
| 1 |
Pilot study 1 |
10 yr MC DSH |
IRIS CKD II; creatinine: 2.5 |
2 × 106 MSCs intravenously × 3 treatments |
| 2 |
Pilot study 1 |
15 yr FS DSH |
IRIS CKD III; creatinine: 3.5 |
2 × 106 MSCs intravenously × 3 treatments |
| 3 |
Pilot study 1 |
7 yr MC Siamese |
IRIS CKD III; creatinine: 4.3 |
2 × 106 MSCs intravenously × 3 treatments |
| 4 |
Pilot study 1 |
12 yr MC DLH |
IRIS CKD II; creatinine: 2.4 |
2 × 106 MSCs intravenously × 3 treatments |
| 5 |
Pilot study 1 |
15 yr MC DSH |
IRIS CKD II; creatinine: 2.3 |
2 × 106 MSCs intravenously × 3 treatments |
| 6 |
Pilot study 1 |
15 yr FS Siamese |
IRIS CKD III; creatinine: 3.5 |
2 × 106 MSCs intravenously × 3 treatments |
| 7 |
Pilot study 2 |
11 yr MC DSH |
IRIS CKD II; creatinine: 1.9 |
4 × 106 MSCs intravenously × 3 treatments |
| 8 |
Pilot study 2 |
11 yr FS DSH |
IRIS CKD II; creatinine: 2.6 |
4 × 106 MSCs intravenously × 3 treatments |
| 9 |
Pilot study 2 |
18 yr FS DSH |
IRIS CKD II; creatinine: 2.8 |
4 × 106 MSCs intravenously × 3 treatments |
| 10 |
Pilot study 2 |
15 yr MC DSH |
IRIS CKD II; creatinine: 2.2 |
4 × 106 MSCs intravenously × 3 treatments |
| 11 |
Pilot study 2 |
7 yr MC DSH |
IRIS CKD III; creatinine: 3.7 |
4 × 106 MSCs intravenously × 3 treatments |
| 12 |
Pilot study 2 |
15 yr MC DSH |
IRIS CKD II; creatinine: 2.3 |
Iohexol GFR repeatability only |
| 13 |
Pilot study 2 |
16 yr MC DSH |
IRIS CKD II; creatinine: 2.1 |
Iohexol GFR repeatability only |
| 14 |
Pilot study 2 |
16 yr MC DSH |
IRIS CKD II; creatinine: 1.8 |
Iohexol GFR repeatability only |
| 15 |
Pilot study 3 |
9 yr MC DSH |
IRIS CKD II; creatinine: 2.6 |
Enrolled but decompensated before treatment initiated |
| 16 |
Pilot study 3 |
15 yr MC Siamese |
IRIS CKD II; creatinine: 2.4 |
4 × 106 MSCs intravenously × 2 treatments before recurrence of previous diabetes |
| 17 |
Pilot study 3 |
13 yr MC Siamese |
IRIS CKD II; creatinine: 2.7 |
4 × 106 MSCs intravenously × 3 treatments |
| 18 |
Pilot study 3 |
8 yr MC DSH |
IRIS CKD II; creatinine: 1.7 |
4 × 106 MSCs intravenously × 3 treatments |
| 19 |
Pilot study 3 |
13 yr MC DSH |
IRIS CKD II; creatinine: 2.0 |
4 × 106 MSCs intravenously × 3 treatments |
| 20 |
Pilot study 3 |
15 yr MC DLH |
IRIS CKD II; creatinine: 2.3 |
4 × 106 MSCs intravenously × 3 treatments |
| 21 | Pilot study 3 | 15 yr FS DSH | IRIS CKD III; creatinine: 3.1 | 4 × 106 MSCs intravenously × 3 treatments |
Six cats were enrolled in pilot study 1 and received 2 × 106 cryopreserved adipose-derived mesenchymal stem cells (aMSCs) per infusion. In pilot study 2 eight cats were enrolled; five received 4 × 106 cryopreserved aMSCs per infusion, and three cats received only iohexol clearance studies. In pilot study 3, seven cats were enrolled; five cats received 4 × 106 cryopreserved aMSCs cultured from cryopreserved adipose per infusion; two cats developed unrelated medical conditions and were removed from the trial. CKD, chronic kidney disease; GFR, glomerular filtration rate. MC = male castrated, FS = female spayed, DSH = domestic shorthair, DLH = domestic long hair, IRIS = International Renal Interest Society.